MURINE SERUM GLYCOPROTEIN gp70 BEHAVES AS AN ACUTE PHASE REACTANT*

BY IKUO HARA, SHOZO IZUI,‡ AND FRANK J. DIXON

From the Department of Immunopathology, Scripps Clinic and Research Foundation, La Jolla, California 92037

Relatively large amounts of a glycoprotein, designated gp70 because of its molecular weight of 70,000 and its structural and immunologic similarity to retroviral envelope protein, circulate in the blood of many murine strains free from any association with viral particles (1–5). Although one finds multiple immunologically and structurally related gp70 in all mice, the structure of this serum gp70 molecule most closely resembles, but is not identical by peptide fingerprint analysis, to the coat protein of xenotropic virus isolated only from NZB and NZB × NZW F1 hybrid (NZB × W) mice (5–7).

The origin of serum gp70 and the mechanisms controlling its expression are still unclear. Although lymphoid cells express virion-free gp70 on their surfaces (8–10), these cells do not seem to be a major source for serum gp70, because neither thymectomy nor splenectomy affects serum levels of gp70 (11). A tissue or organ that is directly or indirectly responsive to testosterone was suggested as the origin of serum gp70 (11); however, no serological or immunohistochemical evidence indicates either production or subsequent release of gp70 into the circulating blood by any organ or tissue.

In recent experiments (12), a single injection of bacterial lipopolysaccharide (LPS)¹ greatly enhanced the expression of serum gp70 in murine strains with high baseline levels of gp70 (>10 μg/ml) such as NZB, NZB × W, NZW, BXSB, DBA/2, 129(GIX⁴), but not in those with lower levels (<5 μg/ml) including C57BL/6, BALB/c, or 129(GIX⁵). This increased expression of serum gp70 was unrelated to the activation of endogenous xenotropic virus or other viral genomes. Therefore, this experimental model seemed suitable for investigation of the cellular origin of serum gp70 and the control mechanism for its production. Our results indicate that serum gp70 behaves like an acute phase reactant (APR) and is synthesized mainly by hepatic cells, as are many other APR and serum proteins.

* Supported in part by grants AI-07007, AG-01743, CA-27849, and CA-16600 from U. S. Public Health Service, and by the Cecil H. and Ida M. Green Research Endowment. This is publication number 2566 from the Immunology Departments, Scripps Clinic and Research Foundation, La Jolla, Calif. 92037.
‡ To whom correspondence should be addressed at the World Health Organization Immunology Research and Training Centre, Centre de Transfusion, Hôpital Cantonal, 1211 Geneva 4, Switzerland.

Abbreviations used in this paper: APR, acute phase reactant; BSA, bovine serum albumin; n-GalN, n-galactosamine; HGG, human gamma globulin; LPS, lipopolysaccharide; MuLV, murine leukemia virus; NPP, native protoplasmic polysaccharides; PBS, phosphate-buffered saline; PLP, periodate-lysine-paraformaldehyde; poly I-poly C, polyriboinosinic-polyribocytidylic acid.

J. Exp. Med. © The Rockefeller University Press • 0022-1007/82/02/0345/13 $1.00
Volume 155 February 1982 345-357
346 SERUM gp70 AS AN ACUTE PHASE REACTANT

Materials and Methods

LPS. LPS purified from Escherichia coli 0111:B4 and a lipid A component from LPS of Salmonella minnesota R595 were generously provided by Dr. D. C. Morrison (Department of Microbiology, Emory University School of Medicine, Atlanta, Ga.). E. coli 0111:B4 LPS extracted by the phenol-water method (13) was further fractionated by Sepharose 4B column chromatography, and fraction II of this preparation was used (14). Native protoplastic polysaccharides (NPP) (15), alkali-treated LPS (16) (both lipid A free), as well as untreated LPS from E. coli 0113 were kindly provided by Dr. J. A. Rudbach (Department of Microbiology, University of Montana, Missoula, Mont.). All LPS and NPP preparations were diluted to the desired concentrations with sterile saline and injected intraperitoneally in a final volume of 0.4 ml.

Mice. All mice used in this study were 6–12 wk old. NZB, NZB × W, BXSB, DBA/2, 129(Gxx+), 129(Gxx-), C57BL/6, and BALB/c mice were obtained from the mouse breeding colony at Scripps Clinic and Research Foundation. Mice were bled from the retroorbital plexus, and the resulting sera were stored at −20°C until use.

T Cell-depleted Mice and Radiation Chimeras. T cell-depleted mice were prepared as follows: 2 mo-old NZB × W male mice were thymectomized, subjected to whole body exposure of 950 rad of 131Cs γ-rays (GammaCell 40, Atomic Energy of Canada Ltd., Ottawa, Can.), and reconstituted with 5 × 10^7 syngeneic bone marrow cells treated with anti-Thy-1.2 sera (New England Nuclear, Boston, Mass.) and guinea pig complement (Pel-Freez Biologicals, Rogers, Ariz.). 16 d after reconstitution, recipients were injected with 25 μg of LPS i.p. and tested for serum gp70 responses. The effectiveness of T cell depletion was demonstrated by the marked impairment of antibody responses to the T dependent antigen, human gamma globulin (HGG), in T cell-depleted mice (24 ± 1 μg/ml) compared with unmanipulated mice (480 ± 35 μg/ml), and by the responsiveness of their spleen cells to 1/μg/ml of concanavalin A (stimulation index of T cell-depleted mice was 3.8 and of unmanipulated mice, 113.2).

Radiation chimeras were made as follows: after 129(Gxx+) and 129 (Gxx-) mice received 900 rad of irradiation, we injected each substrain with 50 × 10^6 spleen cells from the congenic counterpart. 1 mo later, 25 μg of LPS was administered i.p., after which the serum gp70 and IgM responses were monitored.

Assay of gp70. Concentrations of gp70 in sera and tissue extracts of test mice were determined by their capacity to inhibit the binding of goat antibody to feline leukemia virus to 125I-labeled gp70 from Rauscher murine leukemia virus (MuLV). The details of this radioimmunoassay were described previously (17).

Assay of IgM and Anti-HOG. A solid-phase radioimmunoassay was performed to assess the serum levels of IgM. The same assay, but with human IgG used as the antigen, quantitated anti-HOG antibodies in sera after mice received an intravenous injection of 400 μg heat-aggregated HGG. These assays were performed as described (18, 19).

Quantitation of Haptoglobin. Concentrations of haptoglobin in murine serum were measured by radial immunodiffusion in agar with goat anti-human haptoglobin antiserum (N. L. Cappel Laboratories, Cochranville, Pa.) used according to the method of Mancini et al. (20). Results are expressed as a percentage of values from the pooled sera of 3-mo-old C57BL/6 male mice.

Chemical Reagents. Turpentine oil was obtained from American Scientific Products, Irvine, Calif. Polyriboinosinic-polycytidylic acid (poly I-poly C), colchicine and α-galactosamine (α-GalN) were purchased from Sigma Chemical Company, St. Louis, Mo. and dissolved in pyrogen-free saline immediately before use.

Preparation of Tissue Extracts. Samples weighing 0.06–0.2 gr from livers, kidneys, spleens, thymuses, and lungs of test mice were placed in tissue grinders and mixed with cold 0.01 M phosphate-buffered saline (PBS), pH 7.2, to yield a 10% homogenate (wt/vol). These tissue homogenates in an ice bath were sonicated with a Sonifier Cell Disrupter (Heat Systems-Ultrasonics, Inc., Plainview, N. Y.) and then centrifuged at 2,000 g for 15 min at 4°C. The supernatants were treated with Triton X-100 (Rohm and Haas Co., Philadelphia, Pa.) in a final concentration of 0.4% at 37°C for 15 min, followed by three cycles of freezing and thawing and centrifugation at 2,000 g for 15 min at 4°C. The final supernatants were used for the quantitation of tissue gp70.

Determination of gp70 Content in Tissues. Blood content in each tissue extract was quantitated
by using $^{131}$I-labeled bovine serum albumin (BSA; Calbiochem-Behring Corp., American Hoechst Corp., San Diego, Calif.) as a volume marker according to the modified procedure of Mathison and Ulevitch (21). Briefly, 0.2-0.3 mg of $^{131}$I-BSA with a specific activity of 1.5-2.5 $\mu$Ci/$\mu$g was injected intravenously into NZB × W female mice, whose sera were collected 3 h later. The radioactivity of sera with approximately 15-20 $\mu$Ci/ml was >90% precipitable in 10% trichloroacetic acid. 50-100-$\mu$l samples containing $1 \times 10^{5}-2 \times 10^{5}$ cpm of $^{131}$I-BSA were then injected intravenously into 2-mo-old NZB × W female mice 5 min before killing. On the basis of counts per minute per ml of tissue extract and per ml of blood, the blood content in various tissue extracts was calculated. From the measurement of gp70 content in tissue extracts and in blood, the amounts of gp70 present in tissue were computed.

**Fluorescence Microscopy for Detection of gp70 in Livers.** To localize gp70 in livers of test mice, each liver was perfused with 0.05 M PBS, pH 7.2, and with the periodate-lysine-paraformaldehyde (PLP) solution as described by McLean and Nakane (22). Then, 2-4 mm liver fragments were fixed with PLP for 3 h at 4°C and washed, first with 7% sucrose in PBS, then with 15% sucrose in PBS, and finally with PBS containing 25% sucrose and 20% glycerol. The fixed liver samples were embedded in AmesOCT compound, quick frozen, and sectioned into 4-$\mu$m slices on a cryostat at −35°C. To demonstrate gp70 in this tissue, sections were incubated with the IgG fraction of goat anti-Rauscher MuLV gp70 (the gift of Dr. J. H. Elder, Scripps Clinic and Research Foundation) or normal goat IgG for 30 min at room temperature. After being washed, fluorescein isothiocyanate-conjugated rabbit anti-goat IgG (N. L. Cappel Laboratories) was applied for 30 rain at room temperature. The specificity of fluorescence was controlled by absorbing the goat anti-Rauscher MuLV gp70 with Rauscher MuLV. For this purpose, anti-gp70 IgG (0.5 ml of a 6 mg/ml solution) was incubated with 5 mg Rauscher MuLV for 30 min at 37°C, followed by centrifugation at 100,000 $g$ for 60 min at 4°C. The resulting supernatant was used as absorbed antibodies.

### Results

**Induction of High Serum Levels of gp70 in Mice by LPS.** In 2-mo-old NZB female mice whose baseline levels of serum gp70 were 46 ± 12 $\mu$g/ml, the injection of 25 $\mu$g i.p. of LPS from *E. coli* 0111:B4 caused an increase of gp70 to 376 ± 73 $\mu$g/ml within 24 h. This gp70 response was dose related (Fig. 1). Serum gp70 concentrations increased significantly after injection of 25 ng of LPS (137 ± 27 $\mu$g/ml) and reached near-maximal responses with 25 $\mu$g of LPS in NZB mice. Results were similar in strains with high baseline levels of serum gp70 (>10 $\mu$g/ml) such as NZB × W, BxSB, DBA/2, and 129(Gpx+) mice. However, murine strains with low serum gp70 (<5 $\mu$g/ml) such as C57BL/6 or BALB/c mice showed no increase in serum gp70 at any dose of LPS, as described previously (12).

To define that portion of the LPS molecule responsible for stimulating gp70 response, the lipid A fraction extracted from *S. minnesota* R595 LPS and lipid A-free preparations of *E. coli* 0113 LPS, such as NPP and alkali-treated LPS, were tested for gp70-producing capacity in NZB × W mice. The injection of purified lipid A induced serum levels of gp70 about equal to those stimulated by the entire LPS molecule (Table I). In contrast, NPP and alkali-treated LPS preparations, both of which lack the lipid A component, induced only minimal activity.

**Unrelatedness of Serum gp70 Induction by LPS and Activation of Lymphocytes.** Our previous studies (12) demonstrated that the increase in serum gp70 after injection of LPS is not associated with activation of endogenous virus nor attributable to the cellular death caused by LPS, but results from active synthesis of gp70. Because thymocytes express retroviral gp70 on their surfaces (8–10), we now examined the possible participation of T cells in the serum gp70 response stimulated by LPS. After T cell-depleted NZB × W mice (thymectomized and reconstituted with anti-Thy-1.2 and comple-
SERUM gp70 AS AN ACUTE PHASE REACTANT

**Fig. 1.** Serum gp70 responses of 2-mo-old NZB female mice injected with various doses of LPS from *E. coli* 0111:B4. Each point represents a mean value from five mice.

**TABLE I**

| LPS preparations* | Serum gp70 |
|--------------------|------------|
|                    | Day 0 | Day 1 |
| LPS                | 47.3 ± 12.9 | 280.7 ± 41.3 |
| NPP                | 50.1 ± 3.8 | 85.5 ± 17.6 |
| Alkali-treated LPS | 51.5 ± 10.2 | 94.5 ± 39.6 |
| Lipid A            | 44.7 ± 3.1 | 312.5 ± 99.8 |
| Saline             | 48.2 ± 14.5 | 52.2 ± 6.7 |

*50 μg of each LPS preparation was injected i.p. on day 0 into 2-mo-old NZB × W male mice. LPS, NPP, and alkali-treated LPS were purified from *E. coli* 0113 and lipid A from *S. minnesota* R595. Note that both NPP and alkali-treated LPS lacked lipid A.

†Mean ± 1 SD for five mice.

ment-treated syngeneic bone marrow cells) received 25 μg LPS i.p., their serum gp70 responses were compared with those of unmanipulated NZB × W mice. LPS increased serum gp70 levels from 61 ± 22 μg/ml to 336 ± 82 μg/ml in T cell-depleted mice. This increased response was only slightly lower than that in controls with normal numbers of T cells (from 62 ± 11 μg/ml to 590 ± 69 μg/ml), thus excluding a major role of T cells in serum gp70 responses induced by LPS.

LPS is a potent B cell activator (23), and the activation of B cells might account for the enhanced expression of gp70 on their surfaces (24, 25). Therefore, we examined the possible relationship between synthesis of serum gp70 promoted by LPS and the activation of B cells, measured as serum levels of polyclonal IgM antibodies. For this
purpose, 2-mo-old NZB × W mice were lethally irradiated (1,000 rad), and 2 d later, were injected with 25 μg of LPS. 1 d after injection of LPS, concentrations of serum gp70 were ~10 times as high as those before injection of LPS regardless of irradiation (Table II). However, 5 d after the injection of LPS, serum IgM levels doubled in unirradiated mice, but actually dropped in irradiated mice. Radiation alone had no significant effect on serum levels of gp70, but again somewhat decreased the concentrations of serum IgM.

To confirm that the activation of lymphocytes was unrelated to the LPS-induced serum gp70 response, this response was examined in radiation chimeras of 129(Gix +) and 129(Gix -) congenic mice. It had been shown that LPS enhances the expression of serum gp70 in the former high gp70 mice but not in the latter (12), which have much lower concentrations of gp70 in sera and on the surface of lymphocytes (2, 10, 12). Baseline levels of serum gp70 in irradiated 129(Gix +) or 129(Gix -) mice reconstituted with reciprocal spleen cells were comparable to those of untreated 129(Gix +) or 129(Gix -) mice, regardless of the donor's cell type (Table III). Unmanipulated Gix + mice and Gix - mice given Gix - spleen cells responded equally well to the injection of 25 μg of LPS, developing high serum levels of gp70. However, little increase in serum

| Table II |
| --- |
| Serum gp70 and IgM Responses to LPS in Lethally Irradiated NZB × W Mice |
| Treatment | Injection | gp70 Day 0 | gp70 Day 1 | IgM Day 0 | IgM Day 5 |
| Radiation* | LPS | 46.2 ± 5.2 $|$ | 476.1 ± 65.6 | 627 ± 104 | 443 ± 168 |
| None | LPS | 54.2 ± 4.3 | 561.3 ± 53.9 | 530 ± 103 | 1,158 ± 118 |
| Radiation | Saline | 47.1 ± 15.8 | 46.1 ± 3.2 | 632 ± 75 | 442 ± 35 |
| None | Saline | 48.4 ± 5.2 | 54.1 ± 7.6 | 664 ± 8 | 386 ± 61 |

* 2-mo-old NZB × W male mice were irradiated with 1,000 rad 2 d before injection of LPS from *E. coli* 0111:B4.
‡ 25 μg LPS was injected i.p. on day 0.
§ Mean ± 1 SD for six mice.

| Table III |
| --- |
| Failure of Gix - Mice Reconstituted with Gix + Spleen Cells to Produce Serum gp70 after Injection of LPS |
| Mice* | Serum gp70‡ | Serum IgM‡ |
| Day 0 | Day 1 | Day 0 | Day 5 |
| I. Gix + given Gix - cells | 7.0 ± 0.9$|$ | 65.6 ± 13.5 | 253 ± 77 | 946 ± 196 |
| II. Gix + | 8.3 ± 1.3 | 58.4 ± 15.4 | 180 ± 42 | 808 ± 245 |
| III. Gix - given Gix + cells | 1.1 ± 0.3 | 2.2 ± 1.1 | 200 ± 36 | 1,035 ± 232 |
| IV. Gix - | 0.3 ± 0.2 | 1.1 ± 0.8 | 173 ± 15 | 1,038 ± 109 |

* I. Gix + mice reconstituted with Gix - spleen cells.
II. Unmanipulated Gix + mice.
III. Gix - mice reconstituted with Gix + mice.
IV. Unmanipulated Gix - mice.
‡ Serum levels of gp70 and IgM were determined 1 and 5 d, respectively, after injection of 25 μg of LPS from *E. coli* 0111:B4.
§ Mean ± 1 SD for 5-10 mice.
gp70 was seen in 129(Gix-) recipients reconstituted with Gix+ spleen cells or unmanipulated 129(Gix-) mice. It should be noted that a higher frequency of gp70-positive cells in the spleens of Gix- mice reconstituted with Gix+ cells than in Gix+ mice given Gix- cells revealed that spleen cells of both chimeras were of donor type. Further, sera of both groups of mice developed comparable amounts of polyclonal IgM antibodies as a result of B cell activation by LPS (Table III).

Serum gp70 as an APR. Because LPS is a potent inducer of APR (26–28), the kinetics of serum gp70 responses were compared with those of the APR, haptoglobin, in LPS-injected NZB × W female mice. Serum levels of both gp70 and haptoglobin increased as early as 6 h after the injection and peaked at ~24 h, although gp70 levels returned to the preinjection levels more rapidly than those of haptoglobin (Fig. 2). At their peaks, gp70 and haptoglobin levels were ~10 times higher than those before injection of LPS.

The possible stimulation of serum gp70 synthesis by various inducers of APR was also investigated. NZB × W male mice were injected intraperitoneally with 0.01 or 0.05 ml of turpentine oil or 100, 200, or 500 μg of poly I-poly C. 1 d after the injection, dose-dependent increases of serum gp70 and of haptoglobin were observed in the animals injected with turpentine oil or poly I-poly C (Table IV). 0.05 ml of turpentine oil and 500 μg of poly I-poly C induced the production of haptoglobin and serum gp70 as effectively as 25 μg of LPS. This finding was confirmed in DBA/2 and BXSB mice, which are natively high in serum gp70 concentrations (data not shown). Table IV also shows that although LPS stimulated the production of serum IgM as a result of B cell activation, neither turpentine oil nor poly I-poly C elevated the serum levels of IgM, ruling out possible contamination by LPS in preparations of turpentine oil and poly I-poly C.

Tissue Origin of Serum gp70 Induced by LPS. Because, in the foregoing experiments, the induction of serum gp70 by LPS was apparently unrelated to the activation of
TABLE IV

| Inducers* | gp70‡ | Haptoglobin‡ | IgM‡ |
|-----------|-------|-------------|------|
| LPS 25 µg | 590 ± 69§ | 421 ± 52 | 1,640 ± 305 |
| Turpentine oil 0.01 ml | 172 ± 34 | 503 ± 137 | 644 ± 87 |
| 0.05 ml | 413 ± 38 | 533 ± 183 | 523 ± 52 |
| Poly I-poly C 100 µg | 322 ± 84 | 257 ± 46 | 456 ± 133 |
| 200 µg | 426 ± 58 | 307 ± 63 | 507 ± 86 |
| 500 µg | 543 ± 122 | 438 ± 29 | 502 ± 162 |
| Saline | 63 ± 6 | 119 ± 32 | 604 ± 101 |

* Inducers of APR were injected i.p. on day 0 into 2-3-mo-old NZB × W male mice.
‡ Serum levels of gp70 and haptoglobin were determined 1 d after injection and those of IgM, 5 d after.
§ Mean of five to eight mice ± 1 SD.

Fig. 3. The effect of colchicine on the serum gp70 response induced by 25 µg of LPS from E. coli 0111:B4. The different doses of colchicine were injected 3 h after injection of LPS. Each point represents mean ± 1 SD for five mice. O, LPS alone; Δ, LPS + 15 µg colchicine; ●, LPS + 100 µg colchicine; □, 100 µg colchicine; ▲, saline.

lymphocytes, we sought this glycoprotein's site of origin in the liver, a major source of many other serum proteins. The effect of colchicine, an inhibitor of the plasma protein's secretion from the liver, on serum gp70 responses to LPS was examined in NZB × W male mice. Inoculation of 25 µg LPS followed 3 h later by 100 µg of colchicine yielded greatly suppressed rises in serum levels of gp70 compared to those induced by LPS alone (Fig. 3). 12 h after injection of LPS in colchicine-treated mice, serum levels of gp70 were less than one third (133 ± 25 µg/ml) of those in mice receiving LPS alone (449 ± 25 µg/ml). Less, but still significant suppression was observed in mice injected with 15 µg colchicine (215 ± 47 µg/ml). Colchicine alone did not significantly change baseline levels of gp70 in serum.
With this experimental system, the quantity of gp70 in various organs was then determined in NZB × W female mice. The first group of mice were injected with 25 μg LPS alone, the second with 25 μg LPS and 3 h later 100 μg of colchicine, the third with colchicine alone, and the fourth with saline alone (controls). gp70 was quantitated in livers, kidneys, spleens, thymuses, and lungs as well as in sera 9 h after the injection of LPS. The amounts of gp70 recoverable in liver extracts were 3.3 times higher in mice receiving LPS alone than in saline-injected controls (Table V). However, other tissue extracts did not show this remarkable increase in the amounts of gp70. The subsequent injection of colchicine in LPS-treated mice further increased the amounts of gp70 in their livers, but not in any other tissues tested. The liver extracts from such mice contained 2.4 times as much gp70 as those from the animals injected with LPS alone, or 7.8 times as much as those from saline controls, in striking contrast to the blunted serum gp70 responses in colchicine-treated mice. Livers from animals treated with colchicine alone contained 2.3 times higher concentrations of gp70 than saline-injected controls. It was noteworthy that levels of gp70 in sera and livers never increased after injection of LPS administered simultaneously with D-GalN, an inhibitor of protein synthesis (Table VI).

To further identify the cellular origin of gp70, livers from NZB × W mice were analyzed immunohistochemically. Antiserum specific for Rauscher MuLV gp70

### Table V

**Accumulation of gp70 in Livers from Mice Injected with LPS and Colchicine**

| Treatment            | Serum gp70* | Tissue gp70* |
|----------------------|-------------|--------------|
|                      | (μg/ml)     | Liver (μg/organ) | Kidney (μg/organ) | Spleen (μg/organ) | Thymus (μg/organ) | Lung (μg/organ) |
| LPS                  | 329 ± 48    | 50 ± 8       | 29 ± 9           | 14 ± 1           | 12 ± 3           | 11 ± 2          |
| LPS + Colchicine     | 172 ± 30    | 118 ± 23     | 33 ± 5           | 16 ± 1           | 13 ± 2           | 11 ± 2          |
| Colchicine           | 47 ± 14     | 34 ± 5       | 26 ± 4           | 11 ± 1           | 10 ± 4           | 11 ± 2          |
| Saline               | 43 ± 8      | 15 ± 4       | 22 ± 3           | 14 ± 3           | 10 ± 1           | 9 ± 2           |

* Amounts of gp70 in sera and in tissues were determined 9 h after the injection of LPS. Mean ± 1 SD for seven mice.

‡ 25 μg of LPS from *E. coli* 0111:B4 was injected i.p. into 2-mo-old NZB × W female mice.

§ 100 μg of colchicine was injected i.p. 3 h after the injection of LPS.

### Table VI

**Suppression of LPS-Induced gp70 Response in Serum and Liver by D-GalN**

| Treatment   | gp70* (μg/ml) | Serum (μg/organ) | Liver (μg/organ) |
|-------------|---------------|------------------|------------------|
| LPS‡        | 343.5 ± 55.8  | 66.9 ± 12.9      |                  |
| LPS + D-GalN§| 25.4 ± 6.9   | 18.9 ± 2.9       |                  |
| D-GalN      | 18.3 ± 1.6    | 16.5 ± 1.8       |                  |
| Saline      | 36.4 ± 7.5    | 20.2 ± 3.3       |                  |

* Amounts of gp70 in sera and livers were determined 9 h after injection of LPS. Mean ± 1 SD for five mice.

‡ 25 μg of LPS from *E. coli* 0111:B4 was injected i.p. into 2-mo-old NZB × W female mice.

§ 7.5 mg of D-GalN was injected i.p. simultaneously with LPS.
scarcely stained hepatocytes of untreated mice examined by indirect immunofluorescence (Fig. 4A). However, livers of mice obtained 6 h after administration of LPS began to show a fine granular staining of gp70 in most hepatocytes and in some sinusoidal margins, and at 9 h the distribution of gp70 was more extensive. Compared with mice injected with LPS alone, livers from mice receiving both LPS and colchicine showed more intense, coarse granular staining of gp70 in the cytoplasm of virtually all the hepatocytes without appreciable staining along the sinusoids (Fig. 4B). Liver sections from mice treated with colchicine alone also had increased numbers of gp70-positive hepatocytes. After absorption of antisera to Rauscher MuLV gp70 with Rauscher MuLV, no positive staining appeared. Liver sections from BALB/c or C57BL/6 mice, which do not produce gp70 after injection of LPS (12), showed no such specific staining, even after treatment with LPS and colchicine.

Discussion

Using an experimental model in which the expression of serum gp70 is greatly enhanced after the injection of LPS (12), we have demonstrated that this gp70 behaves as an APR and is mainly synthesized by hepatic cells. Apparently, this glycoprotein is significantly involved as an autoantigen in the pathogenesis of murine systemic lupus erythematosus (7, 17, 29–31).

Lymphocytes have been suggested as the major source of serum gp70 (10). Indeed, lymphocytes express surface gp70 molecules with characteristics similar to serum gp70 (10, 32), and enhanced production of serum gp70 induced by LPS is seen only in murine strains whose thymocytes are positive for GIX antigen (12), a type-specific determinant of the gp70 molecule (2, 9, 10, 33). However, our results refute this possibility. First, T cell-depleted mice produce as much serum gp70 as mice with normal numbers of T cells after the injection of LPS. Second, the production of gp70 is independent of the activation of B cells, because lethal irradiation of mice preceding the injection of LPS completely abolishes the activation of B cells, but has no effect

![Fig. 4. Demonstration of gp70 in liver from NZB × W mice injected with LPS and colchicine by indirect immunofluorescence using goat anti-Rauscher MuLV gp70. (A) Liver specimen from uninjected control mice. No specific staining for gp70 is seen on these hepatocytes. (B) Section of liver from mice injected with LPS and colchicine. Colchicine (100 µg) was injected 3 h after the injection of LPS (25 µg) and liver was taken 9 h after LPS injection. Granular staining indicates accumulation of gp70 in cytoplasm of hepatocytes. × 420.](image-url)
on the serum gp70 response. Further, gp70 production is stimulated by such inducers of APR as turpentine oil or poly I-poly C without significant formation of polyclonal IgM antibodies. Finally, 129(GTx+) mice produce gp70 after stimulation with LPS, even after irradiation and reconstitution with spleen cells from Gtx− mice. To the contrary, 129(Gtx−) mice either unmanipulated or replenished with Gtx+ spleen cells develop no serum gp70 responses. This experiment with radiation chimeras clearly indicates that the ability to generate a serum gp70 response is not dependent on the genotype of spleen cells, but rather related to that of nonlymphoid tissues. Of note, both chimeras developed equally high levels of polyclonal antibodies as a result of B cell activation. These results are consistent with a previous report (11) that neither thymectomy, splenectomy, nor exchange of hematopoietic tissues between 129(Gtx+) and 129(Gtx−) mice affected levels of serum gp70 in either strain. All these findings exclude lymphoid cells as a major source of serum gp70.

Instead, our results strongly suggest the liver as the major site of serum gp70 production. The experimental observations that support this conclusion are: First, amounts of gp70 present in liver extracts of LPS-injected mice were more than three times higher than in uninjected controls, whereas no such increase appeared in other tissues including the lung, kidney, spleen, or thymus. Second, the injection of colchicine, which is a known inhibitor of protein release from hepatic cells (34, 35), greatly suppressed the serum gp70 response. Accordingly, increased amounts of gp70 were recoverable from liver extracts but not other tissue extracts, indicating the accumulation of newly synthesized gp70 in hepatic cells as colchicine inhibited its release. Third, o-GaIN, an inhibitor of protein synthesis (36, 37), completely prevented increase of gp70 in the liver or serum after the injection of LPS. Finally, immunohistochemical study more directly showed the presence of gp70 as fine granules in the cytoplasm of hepatic parenchymal cells from mice receiving LPS. Subsequent treatment with colchicine intensified this specific staining by gp70 in almost all the hepatocytes. In all probability, hepatic cells are the major source of the gp70 that eventually enters the circulation. This conclusion is compatible with the fact that the concentration of gp70 in sera is generally 20–100% higher in male mice than females (11, 12, 17). The liver is a known source of several proteins whose serum concentrations are associated markedly with the host’s sex depending on androgenic hormones (38).

A particularly significant observation in this research is that serum gp70 behaves like an APR. Not only LPS but also other inducers of APR, such as turpentine oil or poly I-poly C (39, 40), enhanced the synthesis of serum gp70. Notably, neither turpentine oil nor poly I-poly C activated B cells to produce polyclonal antibodies, ruling out possible contamination with LPS in these preparations. Further, the kinetics of this gp70 response were essentially identical to those of such APR as haptoglobin, serum amyloid A protein, or C-reactive protein (26–28). Finally, we recently demonstrated that restriction of calorie intake in NZB × W mice reduced serum levels of the APR, haptoglobin, as well as gp70, but not that of albumin (41). Consequently, serum gp70 has the qualities of an APR, and its expression is controlled by a mechanism similar to that for other APR. Hepatic cells undoubtedly synthesize gp70 and release it into the circulation as they do other APR (26, 28, 39, 42, 43).

In view of (a) the similarity in expression of serum gp70 and a number of other proteins that are products of the host genome, (b) the failure of other retroviral gene (even env gene) products to be expressed along with serum gp70, and (c) the slight but
demonstrable differences between serum gp70 and the known products of any retroviral env gene, it seems that this molecule behaves as a host gene product.

Summary

A single intraperitoneal injection of bacterial lipopolysaccharide (LPS) or its lipid A component induced high levels of glycoprotein, gp70, in sera of several strains of mice within 24 h. This serum gp70 response induced by LPS was independent of the activation of B cells and the presence of T cells. However, serological and immunohistochemical studies demonstrated the production of gp70 by hepatic parenchymal cells and its subsequent release into the circulating blood.

The expression of gp70 in the serum was enhanced not only by LPS but also other inducers of acute phase reactants (APR) such as turpentine oil or polyriboinosinic-polyribocytidylic acid. Further, the serum gp70 response was kinetically identical to those of APR. These results strongly suggest that (a) the liver may be the major source for serum gp70, (b) serum gp70 behaves like an APR, (c) its expression may be controlled by a mechanism similar to that for other APR, and (d) this glycoprotein apparently behaves as a normal host constituent and not a product of a viral genome.

We thank Dr. John H. Elder for his valuable suggestion and discussion during the course of investigation. The excellent technical assistance of Mr. Cary Lindstrom and the excellent secretarial and editorial assistance of Mr. Kieth L. Dunn, Ms. Nancy Hoffer, and Ms. Phyllis Minick are gratefully acknowledged.

Received for publication 21 September 1981.

References

1. August, J. T., D. P. Bolognesi, E. Fleissner, R. V. Gilden, and R. C. Nowinski. 1974. A proposed nomenclature for the virion proteins of oncogenic RNA viruses. Virology. 60:595.
2. Lerner, R. A., C. B. Wilson, B. C. Del Villano, P. J. McConahey, and F. J. Dixon. 1976. Endogenous oncornaviral gene expression in adult and fetal mice: quantitative, histologic, and physiologic studies of the major viral glycoprotein, gp70. J. Exp. Med. 143:151.
3. Hino, S., J. R. Stephenson, and S. A. Aaronson. 1976. Radioimmunoassays for the 70,000-molecular-weight glycoproteins of endogenous mouse type C viruses: viral antigen expression in normal mouse tissues and sera. J. Virol. 18:933.
4. Strand, M., and J. T. August. 1976. Oncornavirus envelope glycoprotein in serum of mice. Virology. 75:130.
5. Elder, J. H., F. C. Jensen, M. L. Bryant, and R. A. Lerner. 1977. Polymorphism of the major envelope of glycoprotein (gp70) of murine C-type viruses: virion associated and differential antigens encoded by a multi-gene family. Nature (Lond.). 267:23.
6. Elder, J. H., J. W. Gautsch, F. C. Jensen, R. A. Lerner, T. M. Chused, H. C. Morse, J. W. Hartley, and W. P. Rowe. 1980. Differential expression of two distinct xenotropic viruses in NZB mice. Clin. Immunol. Immunopathol. 15:493.
7. Izui, S., J. H. Elder, P. J. McConahey, and F. J. Dixon. 1981. Identification of retroviral gp70 and anti-gp70 antibodies involved in circulating immune complexes in NZB × NZW mice. J. Exp. Med. 153:1151.
8. Del Villano, B. C., B. Nave, B. P. Croker, R. A. Lerner, and F. J. Dixon. 1975. The oncornavirus glycoprotein gp69/71: a constituent of the surface of normal and malignant thymocytes. J. Exp. Med. 141:172.
the G defending thymocyte surface antigen to the gp69/71 envelope glycoprotein of murine leukemia virus. *J. Exp. Med.* 141:198.

10. Obata, Y., H. Ikeda, E. Stockert, and E. A. Boyse. 1975. Relation of GX antigen of thymocytes of envelope glycoprotein of murine leukemia virus. *J. Exp. Med.* 141:188.

11. Obata, Y., E. Stockert, M. Yamaguchi, and E. A. Boyse. 1978. Source and hormone-dependence of Gx-gp70 in mouse serum. *J. Exp. Med.* 148:793.

12. Hara, I., S. Izui, P. J. McConahey, J. H. Elder, F. C. Jensen, and F. J. Dixon. 1981. Induction of high serum levels of retroviral envelope gene products (gp70) in mice by bacterial lipopolysaccharide. *Proc. Natl. Acad. Sci. U. S. A.* 78:4397.

13. Westphal, O., and K. Jann. 1965. Bacterial lipopolysaccharides. Extraction with phenol-water and further applications of the procedure. *Methods Carbohydr. Chem.* 5:83.

14. Morrison, D. C., and L. Leive. 1975. Isolation and characterization of two fractions of lipopolysaccharide from *E. coli* O111:B4. *J. Biol. Chem.* 250:2911.

15. Anacker, R. L., W. D. Bickel, W. T. Haskins, K. C. Milner, E. Ribi, and J. A. Rudbach. 1966. Frequency of occurrence of native hapten among enterobacterial species. *J. Bacteriol.* 91:1427.

16. Nieva, M., C. Milner, E. Ribi, and J. A. Rudbach. 1969. Alteration in physical, chemical and biological properties of endotoxin by treatment with mild alkali. *J. Bacteriol.* 97:1069.

17. Izui, S., P. J. McConahey, A. N. Theofilopoulos, and F. J. Dixon. 1979. Association of circulating retroviral gp70-anti-gp70 immune complexes with murine systemic lupus erythematosus. *J. Exp. Med.* 149:1099.

18. Izui, S., R. A. Eisenberg, and F. J. Dixon. 1979. IgM rheumatoid factors in mice injected with bacterial lipopolysaccharides. *J. Immunol.* 122:2096.

19. Izui, S., D. C. Morrison, B. Curry and F. J. Dixon. 1980. Effect of lipid A-associated protein and lipid A on the expression of lipopolysaccharide activity. I. Immunological activity. *Immunology.* 40:473.

20. Mancini, G., A. Carbonara, and J. Heremans. 1965. Immunochemical quantitation of antigens by single radial immunodiffusion. *Immunochemistry.* 2:235.

21. Mathison, J. C., and R. J. Ulevitch. 1979. The clearance, tissue distribution, and cellular localization of intravenously injected lipopolysaccharide in rabbits. *J. Immunol.* 123:2133.

22. McLean, I. W., and P. K. Nakane. 1974. Periodate-lysine-parafomaldehyde fixative. A new fixative for immunoelectron microscopy. *J. Histochem. Cytochem.* 22:1077.

23. Coutinho, A., and G. Möller. 1973. Thymus-independent B cell induction and paralysis. *Adv. Immunol.* 11:113.

24. Wecker, E., A. Schimpl, and T. Hunig. 1977. Expression of MuLV gp70-like antigen in normal mouse spleen cells induced by antigenic stimulation. *Nature (Lond.)* 269:598.

25. Moroni, C., and G. Schumann. 1977. Are endogenous C-type viruses involved in the immune system? *Nature (Lond.)* 269:600.

26. Koj, A. 1974. Acute-phase reactants. In: Structure and Function of Plasma Proteins. Ed., A. C. Allison. Plenum Publishing Corp. New York. 1:73.

27. Yen-Watson, B., and I. Kushner. 1974. Rabbit CRP response to endotoxin administration: dose-response relationship and kinetics. *Proc. Soc. Exp. Biol. Med.* 146:1132.

28. McAdam, K. P. W. J., and J. D. Sipe. 1976. Murine model for human secondary amylodiosis: genetic variability of the acute-phase serum protein SAA response to endotoxins and casein. *J. Exp. Med.* 144:1121.

29. Yoshiki, T., R. C. Mellors, M. Strand, and J. T. August. 1974. The viral envelope glycoprotein of murine leukemia virus and pathogenesis of immune complex glomerulonephritis of New Zealand mice. *J. Exp. Med.* 140:1011.

30. Izui, S., V. E. Kelley, P. J. McConahey, and F. J. Dixon. 1980. Selective suppression of retroviral gp70-anti-gp70 immune complex formation by prostaglandin E, in murine systemic lupus erythematosus. *J. Exp. Med.* 152:1645.
31. Izui, S., P. J. McConahey, J. P. Clark, L. M. Hang, I. Hara, and F. J. Dixon. 1981. Retroviral gp70 immune complexes in NZB × NZW F2 mice with murine lupus nephritis. J. Exp. Med. 154:517.
32. Morse, H. C., III, T. M. Chused, M. Boehm-Truitt, B. J. Mathieson, S. O. Sharrow, and J. W. Hartley. 1979. XenCSA: cell surface antigens related to the major glycoproteins (gp70) of xenotropic murine leukemia viruses. J. Immunol. 123:443.
33. Stockert, E., L. J. Old, and E. A. Boyse. 1971. The GpX system. A cell surface alloantigen associated with murine leukemia virus; implications regarding chromosomal integration of the viral genome. J. Exp. Med. 133:1334.
34. Stein, O., and Y. Stein. 1973. Colchicine-induced inhibition of very low density lipoprotein release by rat liver in vivo. Biochim. Biophys. Acta. 306:142.
35. Redman, C. M., D. Banerjee, K. Howell, and G. E. Palade. 1975. Colchicine inhibition of plasma protein release from rat hepatocytes. J. Cell. Biol. 66:42.
36. Anukarahanonta, T., H. Shinozuka, and E. Farber. 1973. Inhibition of protein synthesis in rat liver by d-galactosamine. Res. Com. Chem. Pathol. Pharmacol. 5:481.
37. Sipe, J. D. 1978. Induction of the acute-phase serum protein SAA requires both RNA and protein synthesis. Br. J. Exp. Pathol. 59:305.
38. Gustafsson, J. A., P. Eneroth, A. Pousette, P. Skett, C. Sonnenschein, A. Stenberg, and A. Ahlén. 1977. Programming and differentiation of rat liver enzymes. J. Steroid Biochem. 8:429.
39. Courtoy, P. J., C. Lombart, G. Feldmann, N. Moguilevsky, and E. Rogier. 1981. Synchronous increase of four acute phase proteins synthesized by the same hepatocytes during the inflammatory reaction. A combined biochemical and morphologic kinetics study in the rat. Lab. Invest. 44:105.
40. McAdam, K. P. W. J., and J. L. Ryan. 1978. C57BL/10/CR mice: nonresponders to activation by the lipid A moiety of bacterial lipopolysaccharide. J. Immunol. 120:249.
41. Izui, S., G. Fernandes, I. Hara, P. J. McConahey, F. C. Jensen, F. J. Dixon, and R. A. Good. 1981. Low-calorie diet selectively reduces expression of retroviral envelope glycoprotein gp70 in sera of NZB × NZW F1 hybrid mice. J. Exp. Med. 154:1116.
42. Neuhaus, O. W., and A. Liu. 1964. Biochemical significance of serum glycoproteins. III. Hepatic production of a1 and a2 globulins responding to injury. Proc. Soc. Exp. Biol. Med. 117:244.
43. Alper, C. A., D. Raum, Z. L. Awdeh, B. H. Petersen, P. D. Taylor, and T. E. Starzl. 1980. Studies of hepatic synthesis in vivo of plasma proteins, including orosomucoid, transferrin, a1-antitrypsin, C8, and factor B. Clin. Immunol. Immunopathol. 16:94.